Grail Shares Halve After Trial Miss, Partners with Superpower for Galleri Rollout
Grail’s NHS Galleri trial failed to meet its primary endpoint, causing a roughly 50% share price collapse and sparking a Levi & Korsinsky probe into its $290 million cash burn guidance. The company also struck a strategic deal with Superpower to integrate its Galleri multi-cancer blood test into Superpower’s national health platform.
1. Trial Failure and Stock Drop
Grail disclosed that its Galleri multi-cancer early detection trial with the UK’s NHS failed to meet its primary endpoint, triggering a roughly 50% collapse in share value on April 1. The miss raises questions about the test’s sensitivity across multiple cancer types and its potential clinical utility.
2. Levi & Korsinsky Investigation
Within hours of the trial outcome, Levi & Korsinsky launched an investigation into Grail’s prior statements, focusing on its $290 million cash burn projection and whether trial risks were adequately disclosed. The probe will examine if material omissions affected investor decisions.
3. Strategic Superpower Partnership
On the same day, Grail announced a strategic collaboration with Superpower to embed the Galleri blood-based test into Superpower’s preventive health platform nationwide. Members will access Galleri alongside a 100+ biomarker panel, with sample collection available via Quest Diagnostics’ 3,000+ patient access points.